What's Happening?
Milestone Pharmaceuticals has received FDA approval for CARDAMYST, a nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults. This marks the first self-administered treatment
for PSVT, allowing patients to manage episodes outside of healthcare settings. CARDAMYST, a calcium channel blocker, provides rapid relief from symptoms such as rapid heart rate and palpitations. The approval is based on successful clinical trials demonstrating its efficacy and safety. The product is expected to be available in pharmacies by early 2026.
Why It's Important?
The approval of CARDAMYST represents a significant advancement in the treatment of PSVT, a condition affecting over two million Americans. By enabling self-administration, the nasal spray reduces the need for emergency department visits, lowering healthcare costs and improving patient quality of life. This development highlights the potential of innovative drug delivery methods to enhance patient autonomy and treatment accessibility. The approval also positions Milestone Pharmaceuticals as a key player in the cardiovascular treatment market, potentially influencing future drug development strategies.
What's Next?
Milestone plans to launch CARDAMYST in the first quarter of 2026, with efforts underway to secure insurance coverage and distribution channels. The company is also exploring further applications of etripamil, the active ingredient, for conditions like atrial fibrillation with rapid ventricular rate (AFib-RVR). Ongoing research and development may lead to additional indications and expanded market opportunities. The approval may prompt other pharmaceutical companies to pursue similar innovations in drug delivery and patient-centered care.
